Conference abstract · 19 Jun 2017
Conference abstractPublished 20 Apr 2018
Cardiac toxicity risk of long-term use of trastuzumab in metastatic breast cancer: The importance of a cardio-oncology team
Craiova University of Medicine and Pharmacy, Romania
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The prognosis of patients with cancer was substantially improved by early detection and modern treatments, one of these being signaling inhibitors, alone or combined with conventional chemotherapy. Patients receiving cancer therapies may have their quality of life and survival affected by cardiotoxicity, because higher survival rates bring more patients presenting with cardiac adverse effects. Signaling inhibitors like trastuzumab have a risk of cardiovascular adverse effects including cardiac dysfunction and development of heart failure, myocardial ischemia, arrhythmia, QT prolongation, and arterial hypertension. Iatrogenic side effects of these drugs could be irreversible lesions or reversible dysfunction, but exist also the possibility of being overlapped, for example, trastuzumab may produce irreversible cardiac damage in patients with preexisting cardiac dysfunction or augment anthracyclines type I cardiotoxicity. Cardiovascular treatment may delay expression of cardiac dysfunction in these patients. Monitoring the cardiac health of patients before, during and after cancer treatment is very important. It is possible that patient’s eligibility for cancer therapies may be affected and also their life expectancy. In some cases, cancer treatments may be stopped without prompt access to cardio-oncology expertise. Also, patients are not eligible for the aggressive treatments needed, remaining a potential risk of being undertreated, having treatment delays or having dose decreased. Trastuzumab, a monoclonal antibody targeted against HER2/erbB2 and VEGF (vascular endothelial growth factor) signaling pathways, in combination with chemotherapy improved prognosis of women with HER2 overexpressed breast cancer. The main concern of long-term therapy with trastuzumab remains its association with potential cardiotoxicity. Although real, cardiac side effects of trastuzumab are probably overemphasized. I report the case of a woman with metastatic breast cancer, who is currently in complete remission, and who was treated with trastuzumab for more than nine years without significant cardiac toxicity.
Subjects
Oncology & CancerCardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 18 Jul 2016
Echocardiographic methods for preclinical detection of diabetic heart disease and in cardio-oncology
Editorial · 13 Jun 2016
Cardio-Oncology: Between a Rock and a Hard Place
Review article · 2014
Chemoradiotherapy-Associated Cardiovascular Toxicity: A Need of Cardio-Oncology to Improve
Case report · 19 Feb 2023
Long-term response after early discontinuation due to immunotherapy toxicity in metastatic renal cancer: a clinical case and literature review
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOncology & Cancer
- SubjectCardiology
- BylineArticles whose byline prints “Cristina Florescu”
